Circulating Vascular Endothelial Growth Factor and Vascular Cell Adhesion Molecule in Laryngeal Squamous Cell Carcinomas
Authors
Murat Karaman1, Taylan Gün2, Gökhan Altin1, Raşit Cevizci1, Necdet Özçelik1, Ahmet Mahmut Tekin1 and Yildirim Bayazit1 1The Department of Otorhinolaryngology-Head and Neck Surgery at Medipol University, Istanbul, Turkey; 2The Department of Otorhinolaryngology-Head and Neck Surgery at Medicalpark Hospital, Gaziantep, Turkey
Objective: To assess the relationship between the immunohistochemical expression of vascular endothelial growth factor (VEGF) and vascular cell adhesion molecule (VCAM) with the clinical feature of laryngeal squamous cell carcinoma (LSCC). Study Design and Methods: Twenty-nine patients with LSCC were examined as the LSCC group. Twenty-one healthy people who showed no signs of regional or systemic disorders were used as the control group. The staging system for LSCC was determined using American Joint Committee on Cancer (AJCC) 2010 criteria. A quantitative enzyme-linked immunosorbent assay (ELISA) was performed to measure the concentration of soluble serum VEGF and VCAM-1. Results: VEGF levels were higher in the LSCC group compared to the control group (p = 0.001). VCAM levels were not significantly different (p = 0.617). VEGF levels were not correlated to the T and N stage in the LSCC group (p = 0.402). VCAM levels were significantly correlated with the T and N stage (p < 0.0001). Conclusions: VCAM levels could not be used as a tumor marker for diagnosis but were correlated with the stage and, therefore, the aggressivity of the cancer disease.
